With record-breaking revenues and profits accruing on the back of its COVID-19 products, Pfizer is planning a big spend on business development – but chief executive Albert Bourla says the
Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application for TAK-721, a drug candidate that is trying to be the first appro
GlaxoSmithKline's pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory